keyword
MENU ▼
Read by QxMD icon Read
search

peramivir

keyword
https://www.readbyqxmd.com/read/27898328/fate-of-new-three-anti-influenza-drugs-and-one-prodrug-in-the-water-environment
#1
Takashi Azuma, Mao Ishida, Kanae Hisamatsu, Ayami Yunoki, Kana Otomo, Mari Kunitou, Mai Shimizu, Kaori Hosomaru, Shiori Mikata, Yoshiki Mino
We evaluated the environmental fate of new three anti-influenza drugs, favipiravir (FAV), peramivir (PER), and laninamivir (LAN), and an active prodrug of LAN, laninamivir octanoate (LANO), in comparison with four conventional drugs, oseltamivir (OS), oseltamivir carboxylate (OC), amantadine (AMN), and zanamivir (ZAN) by photodegradation, biodegradation, and sorption to river sediments. In addition, we conducted 9-month survey of urban rivers in the Yodo River basin from 2015 to 2016 (including the influenza season) to investigate the current status of occurrence of these drugs in the river environment...
November 26, 2016: Chemosphere
https://www.readbyqxmd.com/read/27881069/anti-influenza-virus-effects-of-catechins-a-molecular-and-clinical-review
#2
Kazuke Ide, Yohei Kawasaki, Koji Kawakami, Hiroshi Yamada
Influenza infection and associated epidemics represent a serious public health problem. Several preventive and curative measures exist against its spread including vaccination and therapeutic agents such as neuraminidase inhibitors (e.g., oseltamivir, zanamivir, as well as peramivir and laninamivir, which are licensed in several countries) and adamantanes (e.g., amantadine and rimantadine). However, neuraminidase inhibitor- and adamantane-resistant viruses have been detected, whereas vaccines exhibit strain-specific effects and are limited in supply...
November 22, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27850318/679-peramivir-for-the-treatment-of-influenza-h1n1-in-critically-ill-pediatric-patients
#3
Robert Witcher, Joanna Tracy, Laura Santos, Arun Chopra
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27845731/influenza-neuraminidase-inhibitors-synthetic-approaches-derivatives-and-biological-activity
#4
REVIEW
Pedro Laborda, Su-Yan Wang, Josef Voglmeir
Despite being a common viral disease, influenza has very negative consequences, causing the death of around half a million people each year. A neuraminidase located on the surface of the virus plays an important role in viral reproduction by contributing to the release of viruses from infected host cells. The treatment of influenza is mainly based on the administration of neuraminidase inhibitors. The neuraminidase inhibitors zanamivir, laninamivir, oseltamivir and peramivir have been commercialized and have been demonstrated to be potent influenza viral neuraminidase inhibitors against most influenza strains...
November 11, 2016: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/27807768/process-chemistry-in-antiviral-research
#5
REVIEW
Yong-Li Zhong, Nobuyoshi Yasuda, Hongming Li, Mark McLaughlin, David Tschaen
This article reviews antiviral therapies that have been approved for human use during the last decade, with a focus on the process chemistry that enabled access to these important drugs. In particular, process chemistry highlights from the practical syntheses of the HCV drugs sofosbuvir (Gilead), grazoprevir (Merck), and elbasvir (Merck), the HIV therapy darunavir (Tibotec) and the influenza treatment peramivir (BioCryst) are presented.
December 2016: Topics in Current Chemistry (Journal)
https://www.readbyqxmd.com/read/27805571/pharmacokinetics-and-safety-of-intravenous-peramivir-neuraminidase-inhibitor-of-influenza-virus-in-healthy-japanese-subjects
#6
Yutaka Saisho, Toru Ishibashi, Hidenori Fukuyama, Hiroyuki Fukase, Jingoro Shimada
BACKGROUND: Intravenous peramivir is a potent neuraminidase (NA) inhibitor with activity against influenza A and B viruses. The early use of NA inhibitors has been shown to reduce mortality in influenza patients. METHODS: To evaluate the pharmacokinetics of peramivir and confirm the safety and tolerability of multiple infusions of peramivir in healthy Japanese subjects, two Phase 1, single-center, randomized, double-blind, and placebo-controlled studies consisting of a multiple-dose study and a high-dose study were conducted...
November 2, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27766921/clinical-efficacy-of-laninamivir-and-peramivir-in-patients-with-seasonal-influenza-a-randomized-clinical-trial
#7
Yusuke Yoshino, Kazunori Seo, Ichiro Koga, Takatoshi Kitazawa, Yasuo Ota
No abstract text is available yet for this article.
October 21, 2016: Infectious Diseases
https://www.readbyqxmd.com/read/27714749/characterization-of-influenza-outbreaks-in-lebanon-during-the-2013-14-and-2014-15-seasons
#8
R Saito, H Akinobu, R A Shaker, I S Akel, A Assaf-Casals, M Lteif, T Odagiri, R Inaba, N Soudani, S Khafaja, S T Ghanem, M Rajab, Y Shobugawa, G S Dbaibo, H Zaraket
Despite the significant burden of influenza outbreaks, active disease monitoring has been largely absent in the Middle East, including Lebanon. In this study we characterized influenza virus in 440 nasopharyngeal swabs collected from patients with acute respiratory infections during two influenza seasons in Lebanon. Influenza A(H3N2) was dominant in the 2013/14 season while the A(H1N1)pdm09 and B/Yamagata strains were most prevalent in the 2014/15 season. All tested isolates were susceptible to 4 neuraminidase inhibitors (oseltamivir, zanamivir, peramivir and laninamivir)...
October 2, 2016: Eastern Mediterranean Health Journal, la Revue de Santé de la Méditerranée Orientale
https://www.readbyqxmd.com/read/27714496/community-and-hospital-acquired-infections-with-oseltamivir-and-peramivir-resistant-influenza-a-h1n1-pdm09-viruses-during-the-2015-2016-season-in-japan
#9
Akinobu Hibino, Hiroki Kondo, Hironori Masaki, Yoshinari Tanabe, Isamu Sato, Nobuhiro Takemae, Takehiko Saito, Hassan Zaraket, Reiko Saito
We report five cases of community- and hospital-acquired infections with oseltamivir- and peramivir-resistant A(H1N1)pdm09 viruses possessing the neuraminidase (NA) H275Y mutation during January-February 2016 in Japan. One case was hospitalized and was receiving oseltamivir for prophylaxis. The remaining four cases were not taking antiviral drugs at the time of sampling. These cases were geographically distant and epidemiologically unrelated. The five viruses showed ~300-fold rise in IC50 values against oseltamivir and peramivir, defined as highly reduced inhibition according to the WHO definition...
October 6, 2016: Virus Genes
https://www.readbyqxmd.com/read/27694694/pharmacokinetics-of-intravenous-peramivir-in-the-airway-epithelial-lining-fluid-of-healthy-volunteers
#10
Yohei Funatsu, Sadatomo Tasaka, Takahiro Asami, Ho Namkoong, Hiroshi Fujiwara, Osamu Iketani, Kazuma Yagi, Yoshifumi Kimizuka, Makoto Ishii, Tomoyasu Nishimura, Haruhiko Ogata, Satoshi Iwata, Tomoko Betsuyaku, Naoki Hasegawa
BACKGROUND: Some subtypes of influenza virus, such as H5N1 and H7N9, cause severe viral pneumonia, for which the intraluminal concentration of the anti-influenza agent in the airway is critical. However, the pharmacokinetics of peramivir, the only available injectable neuraminidase inhibitor formulation, in the airway epithelial lining fluid (ELF) remains unclear. In this study, we aimed to determine the time course of peramivir in the pharyngeal ELF, bronchial ELF and plasma of healthy volunteers using bronchoscopic microsampling technique...
October 3, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27578993/peramivir-injection-in-the-treatment-of-acute-influenza-a-review-of-the-literature
#11
REVIEW
Ashley Wester, Avinash K Shetty
Influenza virus infection is a major cause of morbidity and mortality in children and adults globally. Seasonal epidemics are common due to the rapid virus evolution, whereas the frequent emergence of antigenic variants can result in pandemics and sporadic/endemic avian influenza virus infections. Although annual vaccination is the mainstay for influenza prevention and control, the use of antiviral agents must be considered for treatment and prophylaxis against influenza. Currently available antiviral drugs include neuraminidase inhibitors (NAIs), adamantanes, and a novel polymerase inhibitor (favipiravir)...
2016: Infection and Drug Resistance
https://www.readbyqxmd.com/read/27497712/post-marketing-safety-evaluation-of-the-intravenous-anti-influenza-neuraminidase-inhibitor-peramivir-a-drug-use-investigation-in-patients-with-high-risk-factors
#12
Takuji Komeda, Shingo Ishii, Yumiko Itoh, Masaki Sanekata, Takayoshi Yoshikawa, Jingoro Shimada
Peramivir, the only injectable anti-influenza neuraminidase inhibitor medically available in Japan at present, is considered first-line treatment in patients with high risk factors for influenza exacerbation. We conducted a drug-use investigation of peramivir in inpatients with high risk factors (old age, pregnancy, and underlying disease such as chronic respiratory disease) from January 2010 to March 2013. Data of 772 patients from 124 facilities across Japan were collected; peramivir's safety in 770 patients and effectiveness in 688 patients were examined...
October 2016: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/27478032/discovery-of-cyclosporine-a-and-its-analogs-as-broad-spectrum-anti-influenza-drugs-with-a-high-in%C3%A2-vitro-genetic-barrier-of-drug-resistance
#13
Chunlong Ma, Fang Li, Rami Ghassan Musharrafieh, Jun Wang
As the number of drug-resistant influenza viruses continues to increase, antivirals with novel mechanisms of action are urgently needed. Among the two classes of FDA-approved antiviral drugs, neuraminidase (NA) inhibitors, oseltamivir, zanamivir, and peramivir, are currently the only choice for the prevention and treatment of influenza virus infection. Due to the antigenic drift and antigenic shift, it will only be a matter of time before influenza viruses become completely resistant to these NA inhibitors...
September 2016: Antiviral Research
https://www.readbyqxmd.com/read/27392915/efficacy-of-delayed-treatment-of-china-made-peramivir-with-repeated-intravenous-injections-in-a-mouse-influenza-model-from-clinical-experience-to-basal-experiment
#14
Zhengtu Li, Runfeng Li, Jing Li, Hui Xie, Yanbing Hao, Qiuling Du, Tingting Chen, Yimin Li, Rongchang Chen, Zifeng Yang, Nanshan Zhong
BACKGROUND: China-made Peramivir, an anti-influenza neuraminidase inhibitor drug, is manufactured and widely used in China. Although effective if initiated within 48 h of the onset of symptoms, yet we observed that this drug shows an inconclusive efficacy if treatment is delayed in clinical. Thus we evaluated the efficacy of delayed treatment of China-made Peramivir in a mouse model. METHODS: The mouse model of influenza infection was made and Peramivir was administered intravenously for 5 days following infection, and weight loss, lung index, viral shedding and survival rates were monitored...
2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27374689/persistent-infection-of-drug-resistant-influenza-a-virus-during-chemotherapy-for-malignant-lymphoma
#15
Toru Kawakami, Yukio Hirabayashi, Fumihiro Kawakami, Rei Isobe, Naoto Kaneko, Yuto Mimura, Toshiro Ito, Kiyoshi Furuta, Mami Shimazaki, Hideyuki Nakazawa, Kiyoshi Kitano
We herein report the case of an 80-year-old man with malignant lymphoma who became persistently infected with influenza A virus. Although he was repeatedly treated with NA inhibitors, such as oseltamivir or peramivir, nasal cavity swab tests for influenza A antigen continued to be positive for more than 2 months. Virological analyses revealed that he was infected with the NA inhibitor-resistant A (H3N2) virus possessing an R292K substitution in the NA protein. These findings suggest that a drug-resistant influenza virus strain might selectively survive antiviral therapy in elderly patients with refractory malignant lymphoma undergoing multiple chemotherapies...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27336226/influenza-a-h1n1-pdm09-virus-exhibiting-enhanced-cross-resistance-to-oseltamivir-and-peramivir-due-to-a-dual-h275y-g147r-substitution-japan-march-2016
#16
Emi Takashita, Seiichiro Fujisaki, Masayuki Shirakura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara, Yukie Shimazu, Takeshi Shimomura, Shinji Watanabe, Takato Odagiri
An influenza A(H1N1)pdm09 virus carrying a G147R substitution in combination with an H275Y substitution in the neuraminidase protein, which confers cross-resistance to oseltamivir and peramivir, was detected from an immunocompromised inpatient in Japan, March 2016. This dual H275Y/G147R mutant virus exhibited enhanced cross-resistance to both drugs compared with the single H275Y mutant virus and reduced susceptibility to zanamivir, although it showed normal inhibition by laninamivir.
June 16, 2016: Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles, European Communicable Disease Bulletin
https://www.readbyqxmd.com/read/27330964/association-of-influenza-with-severe-pneumonia-empyema-in-the-community-hospital-and-healthcare-associated-setting
#17
Masafumi Seki, Ryota Fuke, Nozomi Oikawa, Maya Hariu, Yuji Watanabe
UNLABELLED: We presented three cases of influenza-related severe pneumonia/empyema that occurred in one season. CASE 1: A 76-year-old diabetic man, developed empyema as a result of severe community-acquired pneumonia (CAP) secondary to Haemophilus influenzae, as confirmed on sputum culture. Nasal swab was positive for influenza A antigen. After drainage of empyema, intravenous peramivir and piperacillin/tazobactam were administered for 3 days and 2 weeks, respectively, followed by oral levofloxacin for 2 weeks...
2016: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/27319273/virological-response-to-peramivir-treatment-in-adults-hospitalised-for-influenza-associated-lower-respiratory-tract-infections
#18
N Lee, P K S Chan, W W S Tam, M C W Chan, G C Y Lui, A K Kwok, F W S Ko, S S S Ng, I M H Yung, R Y K Wong, D S C Hui
An open-label trial on intravenous peramivir was conducted among adult patients hospitalised for influenza-associated lower respiratory tract complications (LRTCs). Virus culture and quantitative reverse transcription PCR (qRT-PCR) were performed serially until Day 10. Peramivir treatment was associated with viral RNA decline as well as culture and RNA negativity, which occurred at rates comparable with those of oseltamivir: by Day 5, viral load decline -2.5 log10 copies/mL [βinteraction -0.071, standard error (SE) 0...
August 2016: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27317305/pharmacokinetic-properties-of-peramivir-after-single-and-multiple-intravenous-infusions-in-healthy-chinese-volunteers
#19
Ming Zhang, Zhan-Zhang Wang, Xiao-Jia Ni, Li-Zhong Li, Yue-Feng Zhang, Hao-Yang Lu, Huan Peng, Wen-Can Huang, Ling-Fang Shen, Ling-Hui Xiong, De-Wei Shang, Yu-Guan Wen
BACKGROUND AND OBJECTIVES: Peramivir, an antiviral agent for intravenous administration, is used to treat progressive influenza in patients with serious complications. The present study was designed to determine the pharmacokinetics of single and multiple intravenous infusions of peramivir in healthy Chinese subjects. METHODS: Single (150, 300 and 600 mg) and multiple (600 mg) doses of peramivir were intravenously administered to 12 healthy Chinese subjects. There was a 7-day washout period between dosing periods...
September 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27265623/global-update-on-the-susceptibility-of-human-influenza-viruses-to-neuraminidase-inhibitors-2014-2015
#20
Aeron C Hurt, Terry G Besselaar, Rod S Daniels, Burcu Ermetal, Alicia Fry, Larisa Gubareva, Weijuan Huang, Angie Lackenby, Raphael T C Lee, Janice Lo, Sebastian Maurer-Stroh, Ha T Nguyen, Dmitriy Pereyaslov, Helena Rebelo-de-Andrade, Marilda M Siqueira, Emi Takashita, Masato Tashiro, Danielle Tilmanis, Dayan Wang, Wenqing Zhang, Adam Meijer
The World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs...
August 2016: Antiviral Research
keyword
keyword
57476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"